We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
151
Pyxis Oncology
PYXS
$188M
$1.58M 0.02%
+143,640
New +$1.64M
LABP
152
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$1.36M 0.02%
28,322
– –
CABA icon
153
Cabaletta Bio
CABA
$429M
$1.15M 0.01%
302,509
– –
LBPH
154
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$554K 0.01%
113,500
– –
AUGX
155
DELISTED
Augmedix, Inc. Common Stock
AUGX
$278K ﹤0.01%
+88,363
New +$320K
OWLT.WS
156
DELISTED
Owlet, Inc. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
OWLT.WS
$86K ﹤0.01%
+220,704
New +$123K
AZN icon
157
CALL
AstraZeneca
AZN
$270B
– –
-2,600
Closed -$312K
CRSP icon
158
CRISPR Therapeutics
CRSP
$4.62B
– –
-612,700
Closed -$68.6M
ELV icon
159
Elevance Health
ELV
$82.6B
– –
-207,100
Closed -$77.2M
EVH icon
160
CALL
Evolent Health
EVH
$386M
– –
-250,000
Closed -$7.75M
HUMA icon
161
Humacyte
HUMA
$167M
– –
-1,500,000
Closed -$17.4M
KALA icon
162
KALA BIO
KALA
$11.9M
– –
-1,377
Closed -$9.01M
KZR
163
CALL
DELISTED
Kezar Life Sciences
KZR
– –
-11,340
Closed -$980K
KZR
164
DELISTED
Kezar Life Sciences
KZR
– –
-115,000
Closed -$9.94M
MAPSW
165
CALL
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
– –
-150,200
Closed -$649K
MAPS
166
DELISTED
WM TECHNOLOGY INC A
MAPS
– –
-700,400
Closed -$10.2M
NBTX
167
Nanobiotix
NBTX
$1.88B
– –
-500,000
Closed -$5.68M
NVAX icon
168
Novavax
NVAX
$1.2B
– –
-45,580
Closed -$9.45M
OLMA icon
169
Olema Pharmaceuticals
OLMA
$984M
– –
-807,792
Closed -$22.3M
OWLT icon
170
Owlet
OWLT
$146M
– –
-85,714
Closed -$6.71M
PGNY icon
171
Progyny
PGNY
$2.46B
– –
-1,270,045
Closed -$71.1M
PRCT icon
172
Procept Biorobotics
PRCT
$1.03B
– –
-135,000
Closed -$5.15M
REGN icon
173
Regeneron Pharmaceuticals
REGN
$73B
– –
-13,560
Closed -$8.21M
RGEN icon
174
Repligen
RGEN
$7.06B
– –
-14,724
Closed -$4.25M
VRCA icon
175
Verrica Pharmaceuticals
VRCA
$92.9M
– –
-147,973
Closed -$18.5M
4 5 6
7
8

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.